Ying Cheng, Lin Wu, Dingzhi Huang, QiMing Wang, Yun Fan, XiQin Zhang, HuiJie Fan, WenXiu Yao, BaoGang Liu, GuoHua Yu, YueYin Pan, Fei Xu, ZhiYong He, XiaoRong Dong, Rui Ma, XuHong Min, XiaoSong Ge, Hualin Chen, Qun Liu, YanPing Hu, Ying Liu, Chen Yang, Yang Yang, Xiucui Li, Li Zhou
INTRODUCTION: Trilaciclib is a transient cyclin-dependent kinase 4/6 inhibitor that decreases the incidence of chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer (ES-SCLC). TRACES study was designed to assess the safety, efficacy and pharmacokinetics (PK) of trilaciclib before chemotherapy in Chinese patients with ES-SCLC. METHODS: The study included an open-label safety run-in part (Part 1) and double-blinded, placebo-controlled part (Part 2) where patients received trilaciclib or placebo before chemotherapy...
December 31, 2023: Lung Cancer: Journal of the International Association for the Study of Lung Cancer